The Hague: Europe must “close the gap” in vaccination to stop the Covid-19 wave, by driving riding inpatient, the European Union drug watchdog said Thursday.
Warning from the European Medicine Agency (EMA) came when the continent fought with a new wave of pandemic with a case record in several countries.
“We see a number of excessive Covid cases – including Covid severe and hospitalized or entered in the intensive care unit – especially in the” EMA vaccine strategy, “the Marco Cavaleri vaccine strategy said at a press conference.
Some European countries still have a vaccination rate” that cannot be Received low “with most unco condomes, including at risk of more than 50s, he said.” We should not forget that we must close this gap and ensure that as many people will be vaccinated.
“But EMA officials warned that” it is known that not There is a vaccine that is 100 percent effective “so the countries must take other steps to stop the circulated virus during the risky winter.
Some European Union countries have taken or consider steps to target not vaccinated, with Austria which imposes locking on those who have not received Jab Covid.
But effort too Being done to increase vaccine absorption, and to seek new care.
With cases between the children soaring, EMA said it was expected to decide at the beginning of next week whether to approve the Pfizer-Bontech vaccine for the age group 5-11.
Amsterdam-based regulators will also begin to see the new Pfizer anti-covid pills from Friday “considering the critical situation in many member countries”, Cavalry said.
It will allow it to provide scientific advice to countries to use it before formal approval.
Full review for drug approval, which can take months, it is expected to begin next week.
“This drug shows some promising initial results,” Cavaleri said.
Meanwhile, Merck Pharma’s giant rival pill can obtain approval at the end of the year.
Covid pills are seen with potentially breakthroughs because they can be easily and relatively cheaply given to protect risky people, such as parents or those who have problems with the immune system.
Meanwhile, GlaxoSmithKline drug makers have been on Thursday seeking approval for monoclonal antibody treatments, intravenous care also for those who are at risk of severe covid.
This will be the third medicine like that after two new treatments using lab-made antibodies approved last week.